CD8A and neoplasm: A total of 11 immunotherapy markers, namely, TIDE, interferon gamma (IFNG), microsatellite instability (MSI), Merck18, cluster of differentiation (CD) 274, CD8, dysfunction, exclusion, MDSC, CAF, and tumor-associated macrophages M2 (TAMM2), were evaluated.